← Leaderboards
Roberto Pili
Johns Hopkins University
$5,318,216
Attributed
$6,773,444
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $906.3K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,773,444 · 8
By mechanism
R01$3,934,753 · 3
R21$1,594,087 · 4
P50$1,244,604 · 1
Top collaborators
- Naomi B Haas5 shared
- Peter Celestine Hollenhorst5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Steven D Gore$7,773,366
- Peter B Barker$12,208,416
- Victor E Velculescu$5,783,536
- Caren L. Freel Meyers$14,512,343
- Peter R Rapp$7,647,958
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationIn VivoTranslatingInhibitor/AntagonistIn VitroTyrosine Kinase InhibitorPre-ClinicalNovel TherapeuticsBaseHistone Deacetylase InhibitorCombined Modality TherapyRenal Cell CarcinomaRenal CarcinomaBiologicalInsightFutureAngiogenesisChromatin RemodelingAngiogenesis InhibitorsClinical ResearchDrug DevelopmentClinical TrialsPharmacodynamicsMalignant Neoplasm Of Prostate
Grant awards (26)
Therapeutic targeting for translocation renal cell carcinoma$368,288
R01 · FY2025 · CA · contact PI
Therapeutic targeting for translocation renal cell carcinoma$368,288
R01 · FY2024 · CA · contact PI
Epigenetic Mechanisms of Drug Resistance in Renal Cell Carcinoma$429,896
R01 · FY2022 · CA · contact PI
Epigenetic Mechanisms of Drug Resistance in Renal Cell Carcinoma$468,240
R01 · FY2021 · CA · contact PI
Epigenetic mechanisms of drug resistance in renal cell carcinoma$406,936
R01 · FY2020 · CA · contact PI
Epigenetic mechanisms of drug resistance in renal cell carcinoma$417,407
R01 · FY2019 · CA · contact PI
Immunomodulation by dietary protein restriction$123,123
R21 · FY2019 · CA · contact PI
Immunomodulation by dietary protein restriction$74,791
R21 · FY2019 · CA · contact PI
Epigenetic modulation of SEC24D and circulating miR-605 in renal cell carcinoma$70,068
R21 · FY2019 · CA · contact PI
Epigenetic modulation of SEC24D and circulating miR-605 in renal cell carcinoma$68,684
R21 · FY2019 · CA · contact PI
Epigenetic mechanisms of drug resistance in renal cell carcinoma$460,363
R01 · FY2018 · CA · contact PI
Immunomodulation by dietary protein restriction$183,372
R21 · FY2018 · CA · contact PI
Epigenetic modulation of SEC24D and circulating miR-605 in renal cell carcinoma$25,595
R21 · FY2018 · CA · contact PI
Epigenetic modulation of SEC24D and circulating miR-605 in renal cell carcinoma$203,580
R21 · FY2017 · CA · contact PI
Advancing Epidenetic Therapies in Prostate Cancer$137,622
P50 · FY2013 · CA · contact PI
Advancing Epidenetic Therapies in Prostate Cancer$223,933
P50 · FY2012 · CA · contact PI
Advancing Epidenetic Therapies in Prostate Cancer$214,058
P50 · FY2011 · CA · contact PI
Targeting HIF-1alpha in renal cell carcinoma: the role of HDAC inhibitors$341,073
R01 · FY2010 · CA · contact PI
Advancing Epidenetic Therapies in Prostate Cancer$223,030
P50 · FY2010 · CA · contact PI
Enhancing renal cell carcinoma response to IL-2 with the HDAC inhibitor SNDX-275$346,504
R21 · FY2009 · CA · contact PI
Targeting HIF-1alpha in renal cell carcinoma: the role of HDAC inhibitors$336,830
R01 · FY2009 · CA · contact PI
Advancing Epidenetic Therapies in Prostate Cancer$222,984
P50 · FY2009 · CA · contact PI
Targeting HIF-1alpha in renal cell carcinoma: the role of HDAC inhibitors$337,432
R01 · FY2008 · CA · contact PI
Targeting Tumor Angiogenesis with SAHA and Bevacizumab in Kidney Cancer$249,280
R21 · FY2008 · CA · contact PI
Advancing Epidenetic Therapies in Prostate Cancer$222,977
P50 · FY2008 · CA · contact PI
Targeting Tumor Angiogenesis with SAHA and Bevacizumab in Kidney Cancer$249,090
R21 · FY2007 · CA · contact PI